(Reuters) – The U.S. Food and Drug Administration (FDA) on Thursday approved Valneva’s single-shot vaccine for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus.
(Reporting by Bhanvi Satija, Christy Santhosh and Pratik Jain in Bengaluru; Editing by Krishna Chandea Eluri)
